OCARINA II trial shows positive results for ocrelizumab subcutaneous injection in MS
The Phase 3 OCARINA II trial evaluating ocrelizumab has successfully met its primary and secondary endpoints in patients with relapsing forms of multiple sclerosis (MS) or primary progressive MS (PPMS), according to a press release. dThe trial demonstrated that Ocrevus, administered as a twice-yearly 10-minute subcutaneous injection, is non-inferior to the intravenous (IV) infusion form of the drug.
The primary focus of the trial was to assess the pharmacokinetics of Ocrevus subcutaneous injection and compare it to the IV infusion method over a 12-week period. The results showed that the subcutaneous injection maintained comparable levels of the drug in the bloodstream. Additionally, the subcutaneous injection was found to be equally effective in controlling magnetic resonance imaging (MRI) lesion activity in the brain when compared to the IV infusion.
Read the full press release here.